Real-World Evaluation of Treatment Patterns, Healthcare Costs, and Healthcare Resource Utilization Among Patients with Non-small Cell Lung Cancer in the US Receiving Sotorasib

IF 3.4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Therapy Pub Date : 2024-10-29 DOI:10.1007/s12325-024-03020-7

Ihtisham Sultan, David M. Waterhouse, Divyan Chopra, Alexander Lonshteyn, Derek Weycker, Thomas E. Delea, Björn Stollenwerk

{"title":"Real-World Evaluation of Treatment Patterns, Healthcare Costs, and Healthcare Resource Utilization Among Patients with Non-small Cell Lung Cancer in the US Receiving Sotorasib","authors":"Ihtisham Sultan, David M. Waterhouse, Divyan Chopra, Alexander Lonshteyn, Derek Weycker, Thomas E. Delea, Björn Stollenwerk","doi":"10.1007/s12325-024-03020-7","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Sotorasib was the first drug approved for adults with Kirsten rat sarcoma G12C-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) who received prior systemic therapy in the US. This study aimed to provide initial real-world evidence on patient characteristics, treatment patterns, healthcare resource utilization (HCRU), and healthcare costs (HCC) associated with sotorasib in US clinical practice.</p><h3>Methods</h3><p>A retrospective observational study was conducted using the Optum Clinformatics<sup>®</sup> Data Mart US claims database spanning January 2016 to March 2023<i>.</i> The study population included adults with a diagnosis of lung cancer (diagnosis (Dx) date), claims for sotorasib on/post-Dx date (index date), Continuous enrollment for medical/pharmacy benefits from 180 days pre-Dx date to ≥ 30 days post-index date was required. Patients receiving treatments for small-cell lung cancer (SCLC) pre-index were excluded. Outcomes were analyzed for patients receiving sotorasib as second or subsequent line (2L+) treatment and included adherence [proportion of days covered (PDC)], treatment duration, time to next treatment (TTNT), HCRU, and HCC during sotorasib treatment.</p><h3>Results</h3><p>Among 169 patients with lung cancer that met all inclusion criteria, 140 patients received sotorasib as 2L+ treatment (mean age: 71 years; 67.1% females). Mean PDC for sotorasib was 94.9%. Kaplan–Meier median treatment duration was 4.3 months. Median TTNT in patients with subsequent treatment (<i>n</i> = 31) was 6.8 months. During sotorasib treatment, patients had a mean 3.87 outpatient, 0.09 inpatient, and 0.11 emergency visits per month. Mean monthly HCC during sotorasib treatment were US$23,063 versus $25,541 during the 180-day pre-index period.</p><h3>Conclusions</h3><p>Patients in the US receiving sotorasib as 2L+ therapy for NSCLC in real-world clinical practice showed high adherence, TTNT comparable to progression-free survival observed in clinical trials, and HCC similar to those immediately prior to treatment demonstrating real-world benefits with no additional impact on healthcare resources with sotorasib.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"41 12","pages":"4648 - 4659"},"PeriodicalIF":3.4000,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-024-03020-7.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-024-03020-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Sotorasib was the first drug approved for adults with Kirsten rat sarcoma G12C-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) who received prior systemic therapy in the US. This study aimed to provide initial real-world evidence on patient characteristics, treatment patterns, healthcare resource utilization (HCRU), and healthcare costs (HCC) associated with sotorasib in US clinical practice.

Methods

A retrospective observational study was conducted using the Optum Clinformatics^® Data Mart US claims database spanning January 2016 to March 2023. The study population included adults with a diagnosis of lung cancer (diagnosis (Dx) date), claims for sotorasib on/post-Dx date (index date), Continuous enrollment for medical/pharmacy benefits from 180 days pre-Dx date to ≥ 30 days post-index date was required. Patients receiving treatments for small-cell lung cancer (SCLC) pre-index were excluded. Outcomes were analyzed for patients receiving sotorasib as second or subsequent line (2L+) treatment and included adherence [proportion of days covered (PDC)], treatment duration, time to next treatment (TTNT), HCRU, and HCC during sotorasib treatment.

Results

Among 169 patients with lung cancer that met all inclusion criteria, 140 patients received sotorasib as 2L+ treatment (mean age: 71 years; 67.1% females). Mean PDC for sotorasib was 94.9%. Kaplan–Meier median treatment duration was 4.3 months. Median TTNT in patients with subsequent treatment (n = 31) was 6.8 months. During sotorasib treatment, patients had a mean 3.87 outpatient, 0.09 inpatient, and 0.11 emergency visits per month. Mean monthly HCC during sotorasib treatment were US$23,063 versus $25,541 during the 180-day pre-index period.

Conclusions

Patients in the US receiving sotorasib as 2L+ therapy for NSCLC in real-world clinical practice showed high adherence, TTNT comparable to progression-free survival observed in clinical trials, and HCC similar to those immediately prior to treatment demonstrating real-world benefits with no additional impact on healthcare resources with sotorasib.

查看原文本刊更多论文

对美国接受索托拉西布治疗的非小细胞肺癌患者的治疗模式、医疗成本和医疗资源利用情况进行真实世界评估。

简介索托拉西布是美国首个获批用于既往接受过系统性治疗的Kirsten大鼠肉瘤G12C突变局部晚期/转移性非小细胞肺癌（NSCLC）成人患者的药物。本研究旨在就美国临床实践中与索托拉西布相关的患者特征、治疗模式、医疗资源利用率（HCRU）和医疗成本（HCC）提供初步的真实证据：使用 Optum Clinformatics® Data Mart 美国理赔数据库开展了一项回顾性观察研究，时间跨度为 2016 年 1 月至 2023 年 3 月。研究对象包括确诊为肺癌（诊断（Dx）日期）、在诊断日期（索引日期）当日/之后申请索托拉西布治疗的成人。不包括指数前接受小细胞肺癌（SCLC）治疗的患者。对接受索托拉西布作为二线或后续线（2L+）治疗的患者的结果进行了分析，包括索托拉西布治疗期间的依从性[覆盖天数比例（PDC）]、治疗持续时间、下次治疗时间（TTNT）、HCRU和HCC：在符合所有纳入标准的169名肺癌患者中，140名患者接受了索托拉西布的2L+治疗（平均年龄：71岁；67.1%为女性）。索托拉西布的平均PDC为94.9%。Kaplan-Meier 中位治疗时间为 4.3 个月。接受后续治疗的患者（n = 31）的中位 TTNT 为 6.8 个月。在索托拉西布治疗期间，患者平均每月门诊就诊 3.87 次，住院 0.09 次，急诊 0.11 次。索托拉西布治疗期间的平均每月HCC为23063美元，而指数前180天期间为25541美元：在真实世界的临床实践中，接受索托拉西布作为NSCLC 2L+治疗的美国患者表现出很高的依从性，TTNT与临床试验中观察到的无进展生存期相当，HCC与治疗前相似，这表明索托拉西布在真实世界中带来的益处不会对医疗资源造成额外影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.